> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# Verastem Pegs Pro Forma Cash At $422.8 Million, With Runway Into First Half Of 2028
- URL: https://www.bullished.co/verastem-pegs-pro-forma-cash-at-422-8-million-with-runway-into-first-half-of-2028-0e88310c/
- Published: 2026-11-06T12:41:53.000Z
- Updated: 2026-11-06T12:41:53.000Z
- Description: The company says cash plus expected product revenue should last into the first half of 2028, as it lays out 2026-2027 trial milestones.
- Author: Matteo Parrino
- Tags: SEC Filings, VSTM, Industry: Healthcare

[Verastem](https://www.bullished.co/tag/vstm/), which develops cancer drugs aimed at tumors driven by the RAS/MAPK pathway, put its pro forma cash at [$422.8 million](https://www.sec.gov/Archives/edgar/data/0001526119/000110465926123386/tm2628982d2%5Fex99-1.htm?ref=bullished.co) in a corporate presentation furnished Thursday. The company says that cash, combined with expected product revenue, should extend its runway into the first half of 2028.

## From $172.8 million to $422.8 million

The pro forma figure counts cash, equivalents and short-term investments as of September 30 plus $250.0 million in gross proceeds from the October public offering. Without that raise, the balance on September 30 was $172.8 million.

Third-quarter net product revenue from AVMAPKI FAKZYNJA CO-PACK was $24.0 million. GAAP operating expenses for the quarter were $99.2 million, and the company's adjusted operating expenses were $95.2 million.

Shares outstanding were 94.5 million at September 30, excluding 9.7 million shares that unexercised pre-funded warrants could add.

The deck also lists an Oberland revenue-note facility of up to $75 million. Of that, $50 million was funded at closing in August 2026, and the remaining $25 million is available at the company's option if quarterly sales of the product reach at least $40 million by the first quarter of 2027\. The notes carry no financial covenants.

## The ovarian product and a KRAS G12D drug

The company's marketed medicine combines avutometinib and defactinib for adults with KRAS-mutated recurrent low-grade serous ovarian cancer. The deck says demand held steady in the third quarter after significant growth in the second.

The FDA has granted priority review to a blister-pack version of the product, with a target decision date of February 7, 2027\. The company also expects topline results from its Phase 3 confirmatory trial, RAMP 301, by mid-2027.

The second bet is VS-7375, an oral KRAS G12D inhibitor the company calls a potential best-in-class treatment. Data in the deck, which the company first reported in an [October 14 filing](https://www.sec.gov/Archives/edgar/data/0001526119/000110465926115687/tm2627537d4%5F8k.htm?ref=bullished.co), include a 41% confirmed response rate in previously treated pancreatic cancer.

## A crowded trial calendar

Fourth-quarter 2026 targets include opening TARGET-D 301, a Phase 3 trial in first-line pancreatic cancer, completing enrollment in two Phase 2 trials (pancreatic and colorectal), and meeting the FDA on Phase 3 designs for first-line lung and colorectal cancer.

In 2027, the company plans mature colorectal data in the first quarter and initial data from the second-line pancreatic trial and a first-line pancreatic combination in the second quarter. It also plans to complete enrollment in the lung trial in the second quarter and report initial lung and second-line colorectal data in the second half. The deck marks some of these results as intended for a medical meeting.

Management is scheduled to present at investor conferences on November 9, November 10 and November 16.

Learn

- [Item 7.01: Regulation FD disclosure →](https://www.bullished.co/learn/8-k-items-explained/#item-701-regulation-fd-disclosure)  
From 8-K Items Explained: What Every Item Code From 1.01 To 9.01 Tells You, With Examples

### Sources

- [8-K Filing — Verastem, Inc. (VSTM)](https://www.sec.gov/Archives/edgar/data/0001526119/000110465926123386/tm2628982d2%5F8k.htm?ref=bullished.co) — SEC EDGAR
- [Exhibit tm2628982d2\_ex99-1.htm — Verastem, Inc. 8-K exhibit](https://www.sec.gov/Archives/edgar/data/0001526119/000110465926123386/tm2628982d2%5Fex99-1.htm?ref=bullished.co) — SEC EDGAR
- [Verastem Inc (VSTM) Q3 2026 Earnings Call Highlights: Avmapki Revenue Surges 114% as VS-7375 ...](https://nz.finance.yahoo.com/news/verastem-inc-vstm-q3-2026-091841049.html?ref=bullished.co) — Yahoo Finance
- [Verastem, Inc. (VSTM) stock price, news, quote and history - Yahoo Finance](https://uk.finance.yahoo.com/quote/VSTM/?ref=bullished.co) — Yahoo Finance
- [Verastem Oncology to Participate in Upcoming November Investor Conferences](https://www.businesswire.com/news/home/20261102520123/en/Verastem-Oncology-to-Participate-in-Upcoming-November-Investor-Conferences?ref=bullished.co) — businesswire.com
- [8-K filed 2026-10-14 — Verastem, Inc. (earlier disclosure)](https://www.sec.gov/Archives/edgar/data/0001526119/000110465926115687/tm2627537d4%5F8k.htm?ref=bullished.co) — SEC EDGAR

### More on Verastem

- [Verastem Says FDA Agreed To Make Survival A Secondary Goal In Pancreatic Cancer Trial](https://www.bullished.co/verastem-says-fda-agreed-to-make-survival-a-secondary-goal-in-pancreatic-cancer-trial-0aaded1d/)
- [Verastem Prices $250 Million Share Sale At $8.00, Above Last Sale, To Fund KRAS Drug](https://www.bullished.co/verastem-prices-250-million-share-sale-at-8-00-above-last-sale-to-fund-kras-drug-e363447b/)
- [Verastem Prices 30.9 Million Shares At $8.00, Expects About $234.7 Million In Net Proceeds](https://www.bullished.co/verastem-prices-30-9-million-shares-at-8-00-expects-about-234-7-million-in-net-proceeds-d43fa3f9/)

[All Verastem (VSTM) coverage →](https://www.bullished.co/tag/vstm/)